Updated
Neurocrine BiosciencesNBIX · Healthcare
$164.63+3.05%
Market cap$16.7B
IndustryDrug Manufacturers - Specialty & Generic
Neurocrine Biosciences (NBIX) Superinvestor holders
20 of the superinvestors we track hold Neurocrine Biosciences (NBIX) in their latest 13F filings, $2.9B in total.
Summary
The largest holder is Dodge & Cox, with $941M, 0.5% of the portfolio.
In their latest quarter: 2 opened a new position, 7 added, 10 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Dodge & Cox | Added | 5,584,707 | $941M | 0.5% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 3,818,037 | $643M | 0.2% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 2,335,897 | $394M | 0.5% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 2,076,260 | $350M | 0.3% | Q2 2026 |
| Man Group Man Group plc |
Added | 601,019 | $101M | 0.2% | Q2 2026 |
| PRIMECAP Management PRIMECAP Management Co |
Trimmed | 491,340 | $83M | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Added | 371,568 | $63M | 0.1% | Q2 2026 |
| Acadian Acadian Asset Management |
Trimmed | 388,612 | $55M | 0.1% | Q3 2026 |
| Hersh Cohen ClearBridge Investments |
Trimmed | 281,194 | $47M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
Trimmed | 270,754 | $46M | 0.0% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
Added | 205,677 | $35M | 0.1% | Q2 2026 |
| Aziz Hamzaogullari Loomis Sayles & Co |
Added | 182,514 | $31M | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 175,946 | $30M | 0.0% | Q2 2026 |
| Alex Denner Sarissa Capital Management |
Held | 116,533 | $20M | 11.0% | Q2 2026 |
| Jeremy Grantham GMO |
Added | 72,430 | $12M | 0.0% | Q2 2026 |
| Mark Donovan Boston Partners |
Added | 59,268 | $10M | 0.0% | Q2 2026 |
| Arrowstreet Capital | New position | 28,051 | $5M | 0.0% | Q2 2026 |
| Ken Fisher Fisher Investments |
Trimmed | 16,467 | $2M | 0.0% | Q3 2026 |
| David Shaw D. E. Shaw & Co. |
Trimmed | 5,599 | $943,627 | 0.0% | Q2 2026 |
| Alec Litowitz Magnetar Capital |
New position | 2,674 | $450,662 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 20 |
| Q1 2026 | 21 |
| Q4 2025 | 24 |
| Q3 2025 | 24 |
| Q2 2025 | 20 |
| Q1 2025 | 20 |
| Q4 2024 | 19 |
| Q3 2024 | 23 |
Questions about Neurocrine Biosciences
Which superinvestors own Neurocrine Biosciences?
20 of the superinvestors we track hold Neurocrine Biosciences (NBIX) in their latest 13F filings, $2.9B in total. Dodge & Cox, Cliff Asness, Jim Simons, Two Sigma, Man Group, PRIMECAP Management.
Who is the largest superinvestor holder of NBIX?
The largest holder is Dodge & Cox, with $941M, 0.5% of the portfolio.
From Neurocrine Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.